First Manhattan Co. increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 35.3% during the second quarter, Holdings Channel reports. The fund owned 376,395 shares of the specialty pharmaceutical company’s stock after buying an additional 98,300 shares during the period. First Manhattan Co.’s holdings in ANI Pharmaceuticals were worth $17,615,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of the stock. Dimensional Fund Advisors LP increased its stake in ANI Pharmaceuticals by 90.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 91,514 shares of the specialty pharmaceutical company’s stock worth $5,548,000 after buying an additional 43,534 shares during the last quarter. AQR Capital Management LLC bought a new stake in ANI Pharmaceuticals during the fourth quarter worth $252,000. Thrivent Financial for Lutherans increased its stake in ANI Pharmaceuticals by 5.9% in the fourth quarter. Thrivent Financial for Lutherans now owns 4,300 shares of the specialty pharmaceutical company’s stock worth $261,000 after buying an additional 240 shares during the last quarter. Perkins Capital Management Inc. bought a new stake in ANI Pharmaceuticals during the first quarter worth $1,097,000. Finally, CAPROCK Group Inc. increased its stake in ANI Pharmaceuticals by 6.7% in the first quarter. CAPROCK Group Inc. now owns 4,591 shares of the specialty pharmaceutical company’s stock worth $227,000 after buying an additional 287 shares during the last quarter. Institutional investors and hedge funds own 55.54% of the company’s stock.
Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) opened at 46.94 on Wednesday. The company has a market cap of $546.24 million, a PE ratio of 146.69 and a beta of 3.08. The firm’s 50-day moving average is $47.32 and its 200-day moving average is $50.93. ANI Pharmaceuticals, Inc. has a 12 month low of $42.56 and a 12 month high of $70.92.
ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, May 4th. The specialty pharmaceutical company reported $0.74 EPS for the quarter, topping analysts’ consensus estimates of $0.70 by $0.04. The company had revenue of $36.60 million for the quarter, compared to analysts’ expectations of $39.63 million. ANI Pharmaceuticals had a net margin of 2.58% and a return on equity of 23.76%. The firm’s revenue was up 77.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.76 EPS. On average, equities research analysts predict that ANI Pharmaceuticals, Inc. will post $3.84 earnings per share for the current year.
ANIP has been the subject of a number of recent research reports. Guggenheim restated a “buy” rating and issued a $80.00 price objective on shares of ANI Pharmaceuticals in a report on Thursday, April 6th. Zacks Investment Research upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 3rd. Roth Capital set a $56.00 price objective on ANI Pharmaceuticals and gave the company a “hold” rating in a report on Saturday, May 6th. ValuEngine downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Canaccord Genuity initiated coverage on ANI Pharmaceuticals in a report on Monday. They issued a “buy” rating and a $60.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $66.75.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP).
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
